ClinicalTrials.gg
CompletedNCT07948746Updated Nov 19, 2026

Verification of the Efficacy of Salvia Miltiorrhiza Stem Tea for Eye Health.

An interventional study of placebo tea and Salvia miltiorrhiza herbal tea in Eye and Myopia, sponsored by Chung Shan Medical University. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Chung Shan Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 3 months after the study started (first participant enrolled Feb 2021, registered Jun 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 36 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.

Enrollment
26th of 31
36 · median 65
Started
2021
with 3 others
No phase
23 of 40
5 open now
Registered
40th of 40
by date

Among the 40 studies in Myopia with a site in Taiwan, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 23 with no phase, and was the 40th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 20 Years to 36 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Myopia with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether Salvia miltiorrhiza tea can improve visual function and reduce visual discomfort in adults.

The main questions it aims to answer are:

Does Danshen tea improve visual function outcomes compared to placebo? Does Danshen tea reduce symptoms of visual discomfort?

Researchers will compare Danshen tea to a placebo (a similar-looking and tasting beverage without active ingredients) to evaluate its effectiveness.

Participants will:

Consume Danshen tea or a placebo twice daily for 42 days

03

Conditions studied

  • Eye
  • Myopia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 36 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥20 years with the ability to make decisions and act independently.
  • Daily use of 3C products for more than 6 hours (participants with complaints of dry eyes or visual fatigue; Schirmer's test \< 15 mm).
  • Self-reported symptoms of dry eyes and visual fatigue.
  • No history of any ocular surgery (e.g., strabismus surgery, refractive surgery, etc.).

Exclusion criteria

Exclusion Criteria:

  • Presence of systemic diseases that affect the ocular surface.
  • Long-term use of medications or eye drops that affect the condition of the ocular surface.
  • Long-term contact lens users, defined as wearing contact lenses more than 8 times per month.
  • Presence of coagulation-related disorders.
  • Optometry students.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo tea

    Dietary Supplement: placebo tea

  • Experimental
    Salvia miltiorrhiza herbal tea

    Dietary Supplement: Salvia miltiorrhiza herbal tea

Interventions

  • Dietary supplementplacebo tea

    Participants in the intervention group will consume placebo tea twice daily for 42 days. The tea will be prepared using tea bags, each containing 2.5 ± 0.5 g, brewed with 300 ± 50 mL of warm water.

  • Dietary supplementSalvia miltiorrhiza herbal tea

    Participants in the intervention group will consume Salvia miltiorrhiza tea twice daily for 42 days. The tea will be prepared using tea bags, each containing 2.5 ± 0.5 g, brewed with 300 ± 50 mL of warm water.

06

What researchers measure

Primary outcomes

  1. Binocular Accommodative Facility Measured Using ±2.00 D Flipper Lenses (cycles per minute, cpm)

    Binocular accommodative facility (BAF) will be assessed using the standard BAF test with ±2.00 diopter flipper lenses while participants view a near target at 40 cm. One complete accommodative cycle is defined as successfully clearing the target through both the +2.00 D and -2.00 D lenses. The number of complete cycles achieved within one minute will be recorded and expressed as cycles per minute (cpm).

    Time frame: Baseline, Day 21, and Day 42

  2. Near Point of Convergence Measured Using a Royal Air Force (RAF) Ruler (centimeters, cm)

    Near point of convergence (NPC) will be assessed using the standard NPC test with a Royal Air Force (RAF) ruler while participants fixate on a near target moved along the midline toward the eyes. The NPC break point is defined as the distance at which binocular single vision is lost, and the NPC recovery point is defined as the distance at which binocular single vision is regained as the target moves away. Both measurements will be recorded as the distance from the bridge of the nose to the target and expressed in centimeters (cm).

    Time frame: Baseline, Day 21, and Day 42

  3. Amplitude of Accommodation Measured Using a Royal Air Force (RAF) Ruler (diopters, D)

    Amplitude of accommodation (AA) will be assessed using the standard push-up method with a Royal Air Force (RAF) ruler while participants fixate on a near target. The target will be moved gradually toward the participant's eye until sustained blur is first reported. The near point of accommodation will be measured in centimeters (cm) and converted into diopters (D) using the reciprocal of the viewing distance in meters. The calculated accommodative amplitude will be recorded and expressed in diopters (D).

    Time frame: Baseline, Day 21, and Day 42

  4. Macular Pigment Optical Density Measured Using the MPS II or MPS 9000 (Hertz, Hz)

    Macular pigment optical density (MPOD) will be assessed using heterochromatic flicker photometry (HFP) with the MPS II or MPS 9000 device. Participants will respond to a flickering visual stimulus according to the device's standard testing procedure. MPOD will be determined from the HFP measurements and recorded as an optical density value.

    Time frame: Baseline, Day 21, and Day 42

  5. Schirmer's Test Measured Using Standardized Schirmer Strips (millimeters, mm)

    Tear production will be assessed using the Schirmer's test with standardized Schirmer filter paper strips placed in the lower conjunctival fornix. Participants will keep their eyes closed during the 5-minute measurement period. The length of the filter paper wetted by tears will be measured after 5 minutes and recorded in millimeters (mm), with greater wetting lengths indicating higher tear production.

    Time frame: Baseline, Day 21, and Day 42

  6. Tear Break-Up Time Measured Using Fluorescein Staining and a Slit Lamp (seconds, s)

    Tear break-up time (TBUT) will be assessed using the standard fluorescein tear break-up time test with fluorescein staining and a slit-lamp biomicroscope equipped with cobalt blue illumination. Participants will be instructed to blink normally and then keep their eyes open without blinking. The time interval between the last complete blink and the first appearance of a dry spot in the tear film will be measured and recorded in seconds (s). Longer TBUT values indicate greater tear film stability.

    Time frame: Baseline, Day 21, and Day 42

  7. Tear Meniscus Height Measured Using a Slit-Lamp Biomicroscope (millimeters, mm)

    Tear meniscus height (TMH) will be assessed using a slit-lamp biomicroscope. The vertical height of the lower tear meniscus at the central lower eyelid will be measured as the distance between the lower eyelid margin and the upper boundary of the tear meniscus. The measured height will be recorded and expressed in millimeters (mm).

    Time frame: Baseline, Day 21, and Day 42

  8. Dry Eye Symptoms Measured Using the Dry Eye Questionnaire 5 (DEQ-5) (total score)

    Dry eye symptoms will be assessed using the validated 5-item Dry Eye Questionnaire (DEQ-5), which evaluates the frequency and intensity of dry eye symptoms, including ocular discomfort and dryness, as well as the frequency of watery eyes. The total DEQ-5 score ranges from 0 to 22 points, with higher scores indicating more severe dry eye symptoms. The total score will be calculated and recorded for each participant.

    Time frame: Baseline, Day 21, and Day 42

07

Study locations

1 site
  • Chung Shan Medical University
    Taichung, 402, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2021, 7 months.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's 7 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Nov 19, 2026
StartActual
Feb 19, 2021
Primary completionActual
Sep 23, 2021
CompletionActual
Dec 27, 2021
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948746
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Feb 19, 2021
Primary completion
Sep 23, 2021
Completion
Dec 27, 2021
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion